Glucocorticoids and COVID-19
S Bruscoli, PG Puzzovio, M Zaimi, K Tiligada… - Pharmacological …, 2022 - Elsevier
Abstract Coronavirus Disease 19 (COVID-19) is associated with high morbidity and mortality
rates globally, representing the greatest health and economic challenge today. Several …
rates globally, representing the greatest health and economic challenge today. Several …
Flares in lupus nephritis: risk factors and strategies for their prevention
A Banos, G Bertsias - Current Rheumatology Reports, 2023 - Springer
Abstract Purpose of Review Discuss the prognostic significance of kidney flares in patients
with lupus nephritis, associated risk factors, and possible preventative strategies. Recent …
with lupus nephritis, associated risk factors, and possible preventative strategies. Recent …
[HTML][HTML] Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
CC Almeida-Brasil, JG Hanly, M Urowitz… - Annals of the …, 2022 - ard.bmj.com
Objectives To evaluate systemic lupus erythematosus (SLE) flares following
hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance. Methods …
hydroxychloroquine (HCQ) reduction or discontinuation versus HCQ maintenance. Methods …
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer …
AM Scherbakov, SK Vorontsova, AI Khamidullina… - Investigational New …, 2023 - Springer
The promising antitumor effects of progesterone derivatives have been identified in many
studies. However, the specific mechanism of action of this class of compounds has not been …
studies. However, the specific mechanism of action of this class of compounds has not been …
[HTML][HTML] Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
C Fanton, R Furie, V Chindalore, R Levin, I Diab… - Journal of Translational …, 2022 - Elsevier
Objective To evaluate NKTR-358, a polyethylene glycol-interleukin-2 conjugate composition
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
designed to selectively induce regulatory T cells (Tregs), in first-in-human studies. Methods …
The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study
R Chen, R Fu, Z Lin, C Huang, W Huang - Lupus, 2023 - journals.sagepub.com
Objective To investigate the efficacy and safety of telitacicept treatment in a Chinese SLE
cohort, with real-life settings. Methods All patients with SLE who were receiving telitacicept …
cohort, with real-life settings. Methods All patients with SLE who were receiving telitacicept …
Belimumab for systemic lupus erythematosus–Focus on lupus nephritis
M Plüß, S Piantoni, B Tampe, AHJ Kim… - Human Vaccines & …, 2022 - Taylor & Francis
In recent years, advances in the treatment and management of patients with systemic lupus
erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus …
erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus …
The therapeutic strategies for SLE by targeting anti-dsDNA antibodies
Y Wang, S Xiao, Y Xia, H Wang - Clinical reviews in allergy & immunology, 2022 - Springer
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by
diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ …
diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ …
[HTML][HTML] Системная красная волчанка: история и современность
ЕЛ Насонов, СК Соловьев… - Научно-практическая …, 2022 - cyberleninka.ru
Системная красная волчанка (СКВ)-системное аутоиммунное ревматическое
заболевание неизвестной этиологии, характеризующееся гиперпродукцией …
заболевание неизвестной этиологии, характеризующееся гиперпродукцией …
Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
H Zhang, J Chen, Y Zhang, N Zhao, D Xu - Renal Failure, 2023 - Taylor & Francis
Background Belimumab is the first biological agent approved for the treatment of systemic
lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not …
lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not …